3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Evidence-based guide to CJC-1295 modified GRF dosing considerations for Black and African ancestry patients, including pharmacogenomic factors, GH axis variability, and clinical monitoring protocols.
A clinical deep-dive into CJC-1295 (modified GRF) efficacy differences in Hispanic and Latino patients, covering pharmacogenomics, insulin resistance phenotypes, GH axis variation, and practical dosing considerations.
Evidence-based review of CJC-1295 (modified GRF 1-29) safety considerations for South Asian populations, including pharmacogenomic variation, cardiovascular risk at lower BMI thresholds, and clinical monitoring adjustments.